EUVIMEDEUVIMED entdecken
Crossref

Dapagliflozin ameliorates metabolic and hepatic outcomes in a mouse model of metabolic dysfunction-associated steatotic liver disease and diabetes

Xiaoya Sun

Acta Diabetologica · 2025

DOI: 10.1007/s00592-025-02488-1 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Acta Diabetologica, 2025. Verfasst von Xiaoya Sun. Beteiligte Einrichtung: Department of Geriatrics, Beijing Tongren Hospital, Capital Medical University, Beijing, China. sunxiaoya2021@163.com. Hauptthemen laut MEDLINE: Glucosides, Benzhydryl Compounds, Non-alcoholic Fatty Liver Disease, Diabetes Mellitus, Type 2. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 35 Literaturangaben. Gefördert von: Beijing Tongren Hospital.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlucosidesBenzhydryl CompoundsNon-alcoholic Fatty Liver DiseaseDiabetes Mellitus, Type 2LiverAnimalsMiceMice, Inbred C57BLMaleDiet, High-FatInsulin ResistanceDisease Models, AnimalMice, ObeseSodium-Glucose Transporter 2 Inhibitors

Stichwörter der Autor:innen

Insulin resistanceLipidomicsLiverMASLDSGLT2 inhibitorType 2 diabetes

Substanzen

GlucosidesdapagliflozinBenzhydryl CompoundsSodium-Glucose Transporter 2 Inhibitors

Autor:innen und Institutionen

  • Department of Geriatrics, Beijing Tongren Hospital, Capital Medical University, Beijing, China. sunxiaoya2021@163.com.

Förderung

  • Beijing Tongren Hospital

Zitieren

APA

Sun, X. (2025). Dapagliflozin ameliorates metabolic and hepatic outcomes in a mouse model of metabolic dysfunction-associated steatotic liver disease and diabetes. Acta Diabetologica. https://doi.org/10.1007/s00592-025-02488-1

Vancouver

Sun X. Dapagliflozin ameliorates metabolic and hepatic outcomes in a mouse model of metabolic dysfunction-associated steatotic liver disease and diabetes. Acta Diabetologica. 2025. doi:10.1007/s00592-025-02488-1

BibTeX
@article{Sun2025,
  author = {Sun, Xiaoya},
  title = {Dapagliflozin ameliorates metabolic and hepatic outcomes in a mouse model of metabolic dysfunction-associated steatotic liver disease and diabetes},
  journal = {Acta Diabetologica},
  year = {2025},
  doi = {10.1007/s00592-025-02488-1}
}
Kostenlos starten →